In England, NHS data and reported figures indicate that hundreds of children have been prescribed GLP-1 weight-loss medications over the past year, including some who are under 12. The reports point to “more than 400” children in a 12-month period, based on the data cited by outlets.
Context provided across the coverage is that GLP-1 drugs were originally developed to help manage type 2 diabetes, but they have increasingly been used as slimming treatments. The Guardian adds a specific focus on children under 12 and emphasizes that experts call for specialist supervision and long-term monitoring, reflecting concerns about safety and outcomes for younger patients.
The Independent also frames the issue as part of a broader pattern, noting that childhood obesity in England is rising. While the Independent and Guardian describe similar underlying data, their emphasis differs: one highlights the scale of prescribing from NHS data, while the other foregrounds the implications for younger children and the need for careful clinical oversight.
